Literature DB >> 1531638

Alloantigen-specific regulation of cytotoxic T cell responses is mediated through the induction of clonal anergy of CD8+ T cells.

M P Schutze1, P Langlade-Demoyen, C Leclerc.   

Abstract

Priming mice with an alloantigen before immunization with this same alloantigen presented in association with a second one on an F1 stimulator cell inhibits the induction of cytotoxic response directed against the second alloantigen. This inhibition is associated with the induction of a strong cytotoxic T lymphocyte (CTL) response against the first priming alloantigen. For example, a specific suppression of anti-H-2b CTL responses could be induced in C3H/He mice (H-2k) by priming them with H-2d spleen cells before immunization with F1 (H-2dxb) spleen cells. In the present study, we have analyzed the mechanisms underlying this specific suppression of CTL responses. We have demonstrated that the reduction of H-2b-specific CTL responses is reflected by a decrease in the frequency of effector cells specific for H-2b antigen. However, there was no difference in the frequencies of precursor CTL in control and suppressed mice excluding clonal deletion as the mechanism maintaining low responsiveness. Co-culture experiments have shown that the suppression of anti-H-2b CTL responses was not due to suppressor cells but to the failure of CD8+ T cells of suppressed mice to collaborate with normal helper CD4+ T cells. The suppression was therefore ascribed to a functional impairment (clonal anergy) of the CD8+ T cell subset.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531638     DOI: 10.1002/eji.1830220215

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  1 in total

1.  Analysis of T cell responses in liver allograft recipients. Evidence for deletion of donor-specific cytotoxic T cells in the peripheral circulation.

Authors:  J M Mathew; J W Marsh; B Susskind; T Mohanakumar
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.